Related references
Note: Only part of the references are listed.Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
Susan E. Dorman et al.
LANCET INFECTIOUS DISEASES (2018)
Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study
Sabine M. Hermans et al.
BMC INFECTIOUS DISEASES (2017)
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
Heidi Albert et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial
Mina C. Hosseinipour et al.
LANCET (2016)
Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis
Rishi K. Gupta et al.
AIDS (2015)
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF
Gavin J. Churchyard et al.
LANCET GLOBAL HEALTH (2015)
Cell Surface Downregulation of NK Cell Ligands by Patient-Derived HIV-1 Vpu and Nef Alleles
Johanna Galaski et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Empirical treatment for TB in HIV: lessons from a cohort study of people living with HIV treated in Recife, Brazil
Maria de Fatima Pessoa Militao Albuquerque et al.
BMC PUBLIC HEALTH (2014)
Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy
A. Van Rie et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2014)
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial
Grant Theron et al.
LANCET (2014)
Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?
Grant Theron et al.
LANCET INFECTIOUS DISEASES (2014)
Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial
Betina Durovni et al.
PLOS MEDICINE (2014)
Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial
Helen S. Cox et al.
PLOS MEDICINE (2014)
Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis
Simon Walusimbi et al.
BMC INFECTIOUS DISEASES (2013)
Prevalent and Incident Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa
Ankur Gupta et al.
PLOS ONE (2013)
Performance of the 2007 WHO Algorithm to Diagnose Smear-Negative Pulmonary Tuberculosis in a HIV Prevalent Setting
Helena Huerga et al.
PLOS ONE (2012)
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
Catharina C. Boehme et al.
LANCET (2011)
Evaluation of the 2007 WHO Guideline to Improve the Diagnosis of Tuberculosis in Ambulatory HIV-Positive Adults
Olivier Koole et al.
PLOS ONE (2011)